The number of CD14+highCD16−, CD14+highCD16+ and CD14+lowCD16+ monocytes was prospectively investigated in untreated patients with RA before initiation of MTX therapy and during the first 6 months of treatment. This evidence concerns the gene CD14 and rheumatoid arthritis.